AD/PD 2026 Clinical Trial Updates

Dates: March 17-21, 2026 Location: Copenhagen, Denmark Organizer: Kenes Group

Overview

AD/PD 2026 featured significant clinical trial updates across both Alzheimer's disease and Parkinson's disease. This page summarizes the key trial results, regulatory developments, and pipeline advancements presented at the conference["@adpd2026"].

Alzheimer's Disease Clinical Trials

Anti-Amyloid Immunotherapies

Leqembi (Lecanemab) - Eisai/Biogen

The CLARITY-AD trial continue to demonstrate sustained benefits:

Dates: March 17-21, 2026 Location: Copenhagen, Denmark Organizer: Kenes Group

Overview

AD/PD 2026 featured significant clinical trial updates across both Alzheimer's disease and Parkinson's disease. This page summarizes the key trial results, regulatory developments, and pipeline advancements presented at the conference["@adpd2026"].

Alzheimer's Disease Clinical Trials

Anti-Amyloid Immunotherapies

Leqembi (Lecanemab) - Eisai/Biogen

The CLARITY-AD trial continue to demonstrate sustained benefits:

• Phase 3 Extension Data: 36-month follow-up showing maintained cognitive benefits
• Real-World Evidence: Post-approval data supporting clinical effectiveness
• Safety Profile: Updated ARIA monitoring protocols based on real-world use
• Combination Approaches: Trials combining lecanemab with other modalities

Donanemab - Eli Lilly

The TRAILBLAZER-ALZ 2 trial results continue to evolve:

• Population Expansion: Results in broader patient populations
• Biomarker Correlations: Amyloid plaque reduction correlates with clinical outcomes
• Safety Updates: Managing ARIA incidence in clinical practice
• Sequencing Strategies: Planning for treatment-naive vs. prior treatment patients

Gantenerumab - Roche/Genentech

Development program updates:

• SCarlet RoAD and Marguerite RoAD: Long-term follow-up data
• Next-Generation Approaches: Reformulated delivery methods under investigation

Anti-Tau Therapies

Tau Immunotherapy Programs

Multiple anti-tau antibodies advancing through clinical development:

• LMTM (Tau Aggregation Inhibitor) - TauRx: Phase 3 results and regulatory discussions
• Semorinemab - Roche: Phase 2 safety and efficacy data
• JNJ-63733657 - Janssen: First-in-human study results
• APNmAb05 - AbbVie: Early-stage trial updates

Tau PET Tracer Development

Imaging biomarkers for tau pathology:

• PI-2620 - AC Immune/Roche: Cross-validation with neuropathology
• APN-1607 - Aprinoia: Broader applicability in AD spectrum

Neuroinflammation Targets

TREM2 Modulation

Genetic and pharmacologic approaches targeting microglial dysfunction:

• AL002 - Alector/AbbVie: TREM2 agonist clinical development
• AL003 - Alector: Anti-TREM2 antibody programs

Complement Inhibition

Complement pathway as therapeutic target:

• Eculizumab - Alexion: Complement inhibition in neurodegenerative diseases
• APD001 - Apogee: Novel complement modulators

Disease Modification Approaches

Synaptic Protection

• Bryostatin - Neurotrope: PKC modulators for synaptic function
• Lucerstat - Cerenis: HDL mimetics for amyloid clearance

Metabolic Approaches

• T3D-959 - T3D Therapeutics: PPAR delta/gamma agonist
• Pioglitazone - Takeda: Repurposing for AD

Parkinson's Disease Clinical Trials

Alpha-Synuclein-Targeted Therapies

Immunotherapies

Active and passive immunization approaches:

• PRX002 (Pasinersen) - Prothelia/Roche: Anti-alpha-synuclein antisense
• ABBV-951 - AbbVie: Subcutaneous alpha-synuclein antibody
• UCB0599 - UCB: Small molecule alpha-synuclein modulator

Aggregation Inhibitors

Small molecule approaches:

• Anle138b - MODAG: Alpha-synuclein oligomer modulator
• PD01A -AFFiRiS: Active immunization candidate

LRRK2 Inhibitors

DNL151 - Denali/Lilly

LRRK2 inhibitor program updates:

• Phase 1b Results: Target engagement and safety data
• Phase 2 Planning: Dose selection for efficacy studies
• Biomarker Development: pS935-LRRK2 as pharmacodynamic marker

BIIB122 (DNL311) - Denali/Biogen

LRRK2 inhibitor collaboration:

• Clinical Development: Advancement through clinical phases
• Genetic Subgroup Analysis: Response in LRRK2 mutation carriers

Gene Therapy Approaches

AAV-Based Delivery

• AAV2-GAD - Neurologix: Glutamic acid decarboxylase gene therapy
• AAV-AADC - Voyager Therapeutics: Aromatic L-amino acid decarboxylase
• VY-AADC02 - Voyager: Optimized gene delivery for PD

Gene Silencing

• ASOs for GBA - Ionis: Targeting glucocerebrosidase mutations
• SNCA Targeting - UniQure: siRNA approaches for alpha-synuclein reduction

Motor Complications

Levodopa-Induced Dyskinesias

Managing motor complications:

• Levodopa-Carbidopa Intestinal Gel (LCIG) - AbbVie: Long-term outcomes
• ND0612 - Neuroderm: Continuous subcutaneous levodopa delivery
• ABBV-951 - AbbVie: Subcutaneous levodopa/carbidopa pump

Disease Modification

• Inosine - Michael J. Fox Foundation: Urate elevation for neuroprotection
• GDNF - Virin: Glial cell line-derived neurotrophic factor

Neuroprotective Strategies

• CoQ10 - Various: Mitochondrial protection approaches
• Isradipine - NINDS: Calcium channel blockade
• Creatine - NINDS: Energy metabolism support

Biomarker-Driven Trials

Blood-Based Biomarkers in Clinical Trials

Integration of fluid biomarkers for patient selection and monitoring:

• p-Tau217 - Lilly: Regulatory qualification for trial enrichment
• p-Tau181 - Roche: Cross-platform standardization
• NfL - Various: Neurodegeneration monitoring
• α-Synuclein SAA - Various: Seed amplification for PD diagnosis

Precision Medicine Approaches

Genetic stratification in clinical trials:

• GBA Carriers: Specialized trial cohorts for Gaucher disease-associated PD
• LRRK2 Carriers: Targeted enrollment for LRRK2 inhibitor trials
• SNCA Multiplication: Rare genetic subtype studies

Regulatory and Development News

FDA Updates

• Accelerated Approval Pathway: Lessons from recent AD approvals
• Biomarker Qualification: Regulatory pathways for novel biomarkers
• Combination Therapy Guidance: Framework for multi-target approaches

EMA Perspectives

• Adaptive Trial Designs: Flexibility in late-stage development
• Real-World Evidence: Post-approval requirements evolution

Trial Design Innovations

Master Protocols

• Platform Trials: Adaptive designs for multiple interventions
• Basket Trials: histology-agnostic approaches based on biomarkers

Enrichment Strategies

• Biomarker-Positive Selection: Recruiting patients with evidence of target engagement
• Genetic Pre-Screening: Identifying eligible populations early

Remote and Hybrid Trials

• Decentralized Elements: Remote monitoring and virtual visits
• Digital Endpoints: Digital biomarker integration

Future Trial Outlook

Upcoming readouts (2026-2027)

• Multiple anti-amyloid Phase 3 results expected
• LRRK2 inhibitor Phase 2 data anticipated
• Alpha-synuclein immunotherapy results

Pipeline Health

• Over 150 compounds in active clinical development for AD
• Over 80 compounds in active clinical development for PD
• Increasing focus on combination approaches

See Also

• [AD/PD 2026 Conference](/events/adpd-2026)](/events)
• [AD/PD 2026 Scientific Sessions](/events/adpd-2026-scientific-sessions)](/events)
• [AD/PD 2026 Emerging Therapeutic Targets](/events/adpd-2026-emerging-therapeutic-targets)](/events)
• [AD/PD 2026 Company Presentations](/events/adpd-2026-company-presentations)](/events)
• [AD/PD 2026 Plenary Sessions](/events/adpd-2026-plenary-sessions)](/events)
• [Clinical Trials Index](/content/clinical-trials)

References